Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.

Stryker CFO retires and Osiris Therapeutics CEO resigns, as SpineGuard and Tandem Diabetes Care expand management teams.

The case would have tested whether manufacturers could be held liable if an FDA-approved device injured a patient when the product was employed for an off-label, unapproved use. The Oklahoma Federal Court and the 10^th Circuit Court of Appeals had both previously ruled in industry’s favor.

Amidst low growth and a potential rebound in the $9 billion global spine market, the pure-play spine companies, including NuVasive, Globus, K2M and LDR, continue to outperform and grab share from the diversified giants. Medtech Insight founder and former CEO Sharon O'Reilly reports on these companies and more from the 2015 North American Spine Society (NASS) conference in Chicago, where the latest news centered around ancillary approaches to fusion, patient-specific tools, robotics, biologics, expandable cages, MIS and cervical discs.